Peptides and proteins in plasma and cerebrospinal fluid as biomarkers for the prediction, diagnosis, and monitoring of therapeutic efficacy of Alzheimer's disease

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1782, Issue 10, 2008, Pages 549-558

  Aluise, Christopher D ^a   Sowell, Renã A ^a   Butterfield, D Allan ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Alzheimer's disease; Biomarker; CSF; Plasma

Indexed keywords

AD7C NEURAL THREAD PROTEIN; ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN ANTIBODY; AMYLOID BETA PROTEIN[1-42]; ANTIOXIDANT; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CHOLESTEROL; COMPLEMENT FACTOR H; CORTISONE; DONEPEZIL; GALANTAMINE; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; IMMUNOGLOBULIN; ISOPROSTANE DERIVATIVE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; NEURAL THREAD PROTEIN; NEUROFILAMENT PROTEIN; PRAVASTATIN; PROTEIN; RIVASTIGMINE; SIMVASTATIN; TAURINE TRANSPORTER; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; BLOOD ANALYSIS; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DIET; DIETARY INTAKE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG EFFICACY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOTHERAPY; LIFESTYLE; MENINGOENCEPHALITIS; MINI MENTAL STATE EXAMINATION; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NERVE CELL NECROSIS; NONHUMAN; PASSIVE IMMUNIZATION; PHYSICAL ACTIVITY; PLASMA; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN DETERMINATION; PROTEIN URINE LEVEL; PROTEOMICS; REVIEW; SCORING SYSTEM; TREATMENT OUTCOME; URINALYSIS; URINE;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; BLOOD PROTEINS; CEREBROSPINAL FLUID; DEMENTIA; HUMANS; PEPTIDES; PROTEINS; SENSITIVITY AND SPECIFICITY;

EID: 52349099782     PISSN: 09254439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbadis.2008.07.008     Document Type: Review

References (159)

1. Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group, Neurobiol. Aging 19 (1998) 109-116.
2. Issaq H.J., Xiao Z., and Veenstra T.D. Serum and plasma proteomics. Chem. Rev. 107 (2007) 3601-3620
3. Xu G., Zhang H., Zhang S., Fan X., and Liu X. Plasma fibrinogen is associated with cognitive decline and risk for dementia in patients with mild cognitive impairment. Int. J. Clin. Pract. (2007)
4. van Oijen M., Witteman J.C., Hofman A., Koudstaal P.J., and Breteler M.M. Fibrinogen is associated with an increased risk of Alzheimer disease and vascular dementia. Stroke 36 (2005) 2637-2641
5. Thadikkaran L., Siegenthaler M.A., Crettaz D., Queloz P.A., Schneider P., and Tissot J.D. Recent advances in blood-related proteomics. Proteomics 5 (2005) 3019-3034
6. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., and Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129 (2006) 3042-3050
7. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., and Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285 (1991) 111-114
8. Strohmeyer R., Ramirez M., Cole G.J., Mueller K., and Rogers J. Association of factor H of the alternative pathway of complement with agrin and complement receptor 3 in the Alzheimer's disease brain. J. Neuroimmunol. 131 (2002) 135-146
9. Cucullo L., Marchi N., Marroni M., Fazio V., Namura S., and Janigro D. Blood-brain barrier damage induces release of alpha2-macroglobulin. Mol. Cell. Proteomics. 2 (2003) 234-241
10. Zipser B.D., Johanson C.E., Gonzalez L., Berzin T.M., Tavares R., Hulette C.M., Vitek M.P., Hovanesian V., and Stopa E.G. Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging 28 (2007) 977-986
11. Tanzi R.E. A genetic dichotomy model for the inheritance of Alzheimer's disease and common age-related disorders. J. Clin. Invest. 104 (1999) 1175-1179
12. Blacker D., Wilcox M.A., Laird N.M., Rodes L., Horvath S.M., Go R.C., Perry R., Watson Jr. B., Bassett S.S., McInnis M.G., Albert M.S., Hyman B.T., and Tanzi R.E. Alpha-2 macroglobulin is genetically associated with Alzheimer disease. Nat. Genet. 19 (1998) 357-360
13. Maes O.C., Kravitz S., Mawal Y., Su H., Liberman A., Mehindate K., Berlin D., Sahlas D.J., Chertkow H.M., Bergman H., Melmed C., and Schipper H.M. Characterization of alpha1-antitrypsin as a heme oxygenase-1 suppressor in Alzheimer plasma. Neurobiol. Dis. 24 (2006) 89-100
14. Yu H.L., Chertkow H.M., Bergman H., and Schipper H.M. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3 (2003) 2240-2248
15. Wetterling T., and Tegtmeyer K.F. Serum alpha 1-antitrypsin and alpha 2-macroglobulin in Alzheimer's and Binswanger's disease. Clin. Investig. 72 (1994) 196-199
16. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., and Gracy R.W. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293 (2002) 1566-1570
17. Gollin P.A., Kalaria R.N., Eikelenboom P., Rozemuller A., and Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3 (1992) 201-203
18. Moraga F., and Janciauskiene S. Activation of primary human monocytes by the oxidized form of alpha1-antitrypsin. J. Biol. Chem. 275 (2000) 7693-7700
19. Matsubara E., Hirai S., Amari M., Shoji M., Yamaguchi H., Okamoto K., Ishiguro K., Harigaya Y., and Wakabayashi K. Alpha 1-antichymotrypsin as a possible biochemical marker for Alzheimer-type dementia. Ann. Neurol. 28 (1990) 561-567
20. Hinds T.R., Kukull W.A., Van Belle G., Schellenberg G.D., Villacres E.C., and Larson E.B. Relationship between serum alpha 1-antichymotrypsin and Alzheimer's disease. Neurobiol. Aging 15 (1994) 21-27
21. Lieberman J., Schleissner L., Tachiki K.H., and Kling A.S. Serum alpha 1-antichymotrypsin level as a marker for Alzheimer-type dementia. Neurobiol. Aging 16 (1995) 747-753
22. Licastro F., Parnetti L., Morini M.C., Davis L.J., Cucinotta D., Gaiti A., and Senin U. Acute phase reactant alpha 1-antichymotrypsin is increased in cerebrospinal fluid and serum of patients with probable Alzheimer disease. Alzheimer Dis. Assoc. Disord. 9 (1995) 112-118
23. Licastro F., Morini M.C., Polazzi E., and Davis L.J. Increased serum alpha 1-antichymotrypsin in patients with probable Alzheimer's disease: an acute phase reactant without the peripheral acute phase response. J. Neuroimmunol. 57 (1995) 71-75
24. Licastro F., Masliah E., Pedrini S., and Thal L.J. Blood levels of alpha-1-antichymotrypsin and risk factors for Alzheimer's disease: effects of gender and apolipoprotein E genotype. Dement. Geriatr. Cogn. Disord. 11 (2000) 25-28
25. Licastro F., Pedrini S., Caputo L., Annoni G., Davis L.J., Ferri C., Casadei V., and Grimaldi L.M. Increased plasma levels of interleukin-1, interleukin-6 and alpha-1-antichymotrypsin in patients with Alzheimer's disease: peripheral inflammation or signals from the brain?. J. Neuroimmunol. 103 (2000) 97-102
26. Pirttila T., Mehta P.D., Frey H., and Wisniewski H.M. Alpha 1-antichymotrypsin and IL-1 beta are not increased in CSF or serum in Alzheimer's disease. Neurobiol. Aging 15 (1994) 313-317
27. Kuiper M.A., van Kamp G.J., Bergmans P.L., Scheltens P., and Wolters E.C. Serum alpha 1-antichymotrypsin is not a useful marker for Alzheimer's disease or dementia in Parkinson's disease. J. Neural. Transm. Park. Dis. Dement. Sect. 6 (1993) 145-149
28. Scacchi R., Ruggeri M., Gambina G., Martini M.C., Ferrari G., and Corbo R.M. Plasma alpha1-antichymotrypsin in Alzheimer's disease; relationships with APOE genotypes. Neurobiol. Aging 22 (2001) 413-416
29. DeKosky S.T., Ikonomovic M.D., Wang X., Farlow M., Wisniewski S., Lopez O.L., Becker J.T., Saxton J., Klunk W.E., Sweet R., Kaufer D.I., and Kamboh M.I. Plasma and cerebrospinal fluid alpha1-antichymotrypsin levels in Alzheimer's disease: correlation with cognitive impairment. Ann. Neurol. 53 (2003) 81-90
30. Abraham C.R., Selkoe D.J., and Potter H. Immunochemical identification of the serine protease inhibitor alpha 1-antichymotrypsin in the brain amyloid deposits of Alzheimer's disease. Cell 52 (1988) 487-501
31. Aksenova M.V., Aksenov M.Y., Butterfield D.A., and Carney J.M. alpha-1-antichymotrypsin interaction with A beta (1-40) inhibits fibril formation but does not affect the peptide toxicity. Neurosci. Lett. 211 (1996) 45-48
32. Aksenov M.Y., Aksenova M.V., Carney J.M., and Butterfield D.A. Alpha 1-antichymotrypsin interaction with A beta (1-42) does not inhibit fibril formation but attenuates the peptide toxicity. Neurosci. Lett. 217 (1996) 117-120
33. Padmanabhan J., Levy M., Dickson D.W., and Potter H. Alpha1-antichymotrypsin, an inflammatory protein overexpressed in Alzheimer's disease brain, induces tau phosphorylation in neurons. Brain 129 (2006) 3020-3034
34. Liu H.C., Hu C.J., Chang J.G., Sung S.M., Lee L.S., Yuan R.Y., and Leu S.J. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21 (2006) 155-161
35. Merched A., Xia Y., Visvikis S., Serot J.M., and Siest G. Decreased high-density lipoprotein cholesterol and serum apolipoprotein AI concentrations are highly correlated with the severity of Alzheimer's disease. Neurobiol. Aging 21 (2000) 27-30
36. Zolg W. The proteomic search for diagnostic biomarkers: lost in translation?. Mol. Cell. Proteomics. 5 (2006) 1720-1726
37. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., and Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 60 (2003) 958-964
38. Irizarry M.C. Biomarkers of Alzheimer disease in plasma. NeuroRx 1 (2004) 226-234
39. Kuo Y.M., Emmerling M.R., Lampert H.C., Hempelman S.R., Kokjohn T.A., Woods A.S., Cotter R.J., and Roher A.E. High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 257 (1999) 787-791
40. Kuo Y.M., Kokjohn T.A., Kalback W., Luehrs D., Galasko D.R., Chevallier N., Koo E.H., Emmerling M.R., and Roher A.E. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem. Biophys. Res. Commun. 268 (2000) 750-756
41. Zetterberg H., and Blennow K. Plasma Abeta in Alzheimer's disease-up or down?. Lancet Neurol. 5 (2006) 638-639
42. Abdullah L., Paris D., Luis C., Quadros A., Parrish J., Valdes L., Keegan A.P., Mathura V., Crawford F., and Mullan M. The influence of diagnosis, intra- and inter-person variability on serum and plasma Abeta levels. Neurosci. Lett. 428 (2007) 53-58
43. Hampel H., Goernitz A., and Buerger K. Advances in the development of biomarkers for Alzheimer's disease: from CSF total tau and Abeta(1-42) proteins to phosphorylated tau protein. Brain Res. Bull. 61 (2003) 243-253
44. Blennow K. CSF biomarkers for mild cognitive impairment. J. Intern. Med. 256 (2004) 224-234
45. Formichi P., Battisti C., Radi E., and Federico A. Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease. J. Cell. Physiol. 208 (2006) 39-46
46. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., and Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
47. Daly N.L., Hoffmann R., Otvos Jr. L., and Craik D.J. Role of phosphorylation in the conformation of tau peptides implicated in Alzheimer's disease. Biochemistry 39 (2000) 9039-9046
48. Mandelkow E.M., Stamer K., Vogel R., Thies E., and Mandelkow E. Clogging of axons by tau, inhibition of axonal traffic and starvation of synapses. Neurobiol. Aging 24 (2003) 1079-1085
49. Butterfield D.A., Abdul H.M., Opii W., Newman S.F., Joshi G., Ansari M.A., and Sultana R. Pin1 in Alzheimer's disease. J. Neurochem. 98 (2006) 1697-1706
50. Arai H., Terajima M., Miura M., Higuchi S., Muramatsu T., Machida N., Seiki H., Takase S., Clark C.M., Lee V.M., et al. Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer's disease. Ann. Neurol. 38 (1995) 649-652
51. Riemenschneider M., Wagenpfeil S., Vanderstichele H., Otto M., Wiltfang J., Kretzschmar H., Vanmechelen E., Forstl H., and Kurz A. Phospho-tau/total tau ratio in cerebrospinal fluid discriminates Creutzfeldt-Jakob disease from other dementias. Mol. Psychiatry 8 (2003) 343-347
52. Otto M., Wiltfang J., Tumani H., Zerr I., Lantsch M., Kornhuber J., Weber T., Kretzschmar H.A., and Poser S. Elevated levels of tau-protein in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurosci. Lett. 225 (1997) 210-212
53. Buerger K., Otto M., Teipel S.J., Zinkowski R., Blennow K., DeBernardis J., Kerkman D., Schroder J., Schonknecht P., Cepek L., McCulloch C., Moller H.J., Wiltfang J., Kretzschmar H., and Hampel H. Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt-Jakob disease. Neurobiol. Aging 27 (2006) 10-15
54. Tapiola T., Overmyer M., Lehtovirta M., Helisalmi S., Ramberg J., Alafuzoff I., Riekkinen Sr. P., and Soininen H. The level of cerebrospinal fluid tau correlates withneurofibrillary tangles in Alzheimer's disease. Neuroreport 8 (1997) 3961-3963
55. Buerger K., Ewers M., Pirttila T., Zinkowski R., Alafuzoff I., Teipel S.J., DeBernardis J., Kerkman D., McCulloch C., Soininen H., and Hampel H. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 129 (2006) 3035-3041
56. Buerger K., Alafuzoff I., Ewers M., Pirttila T., Zinkowski R., and Hampel H. No correlation between CSF tau protein phosphorylated at threonine 181 with neocortical neurofibrillary pathology in Alzheimer's disease. Brain 130 (2007) e82
57. Engelborghs S., Sleegers K., Cras P., Brouwers N., Serneels S., De Leenheir E., Martin J.J., Vanmechelen E., Van Broeckhoven C., and De Deyn P.P. No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130 (2007) 2320-2326
58. van Gool W.A., Kuiper M.A., Walstra G.J., Wolters E.C., and Bolhuis P.A. Concentrations of amyloid beta protein in cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 37 (1995) 277-279
59. Motter R., Vigo-Pelfrey C., Kholodenko D., Barbour R., Johnson-Wood K., Galasko D., Chang L., Miller B., Clark C., Green R., et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann. Neurol. 38 (1995) 643-648
60. Southwick P.C., Yamagata S.K., Echols Jr. C.L., Higson G.J., Neynaber S.A., Parson R.E., and Munroe W.A. Assessment of amyloid beta protein in cerebrospinal fluid as an aid in the diagnosis of Alzheimer's disease. J. Neurochem. 66 (1996) 259-265
61. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., and Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci. 21 (2001) 372-381
62. Otto M., Esselmann H., Schulz-Shaeffer W., Neumann M., Schroter A., Ratzka P., Cepek L., Zerr I., Steinacker P., Windl O., Kornhuber J., Kretzschmar H.A., Poser S., and Wiltfang J. Decreased beta-amyloid1-42 in cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. Neurology 54 (2000) 1099-1102
63. Maddalena A., Papassotiropoulos A., Muller-Tillmanns B., Jung H.H., Hegi T., Nitsch R.M., and Hock C. Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42. Arch. Neurol. 60 (2003) 1202-1206
64. Lee J.W., Namkoong H., Kim H.K., Kim S., Hwang D.W., Na H.R., Ha S.A., Kim J.R., and Kim J.W. Fibrinogen gamma-A chain precursor in CSF: a candidate biomarker for Alzheimer's disease. BMC Neurol. 7 (2007) 14
65. Korolainen M.A., Nyman T.A., Nyyssonen P., Hartikainen E.S., and Pirttila T. Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin. Chem. 53 (2007) 657-665
66. Davidsson P., and Sjogren M. Proteome studies of CSF in AD patients. Mech. Ageing. Dev. 127 (2006) 133-137
67. Davies L., Wolska B., Hilbich C., Multhaup G., Martins R., Simms G., Beyreuther K., and Masters C.L. A4 amyloid protein deposition and the diagnosis of Alzheimer's disease: prevalence in aged brains determined by immunocytochemistry compared with conventional neuropathologic techniques. Neurology 38 (1988) 1688-1693
68. Hansson O., Zetterberg H., Buchhave P., Londos E., Blennow K., and Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5 (2006) 228-234
69. Petersen R.C. Mild cognitive impairment as a diagnostic entity. J. Intern. Med. 256 (2004) 183-194
70. Andreasen N., Vanmechelen E., Vanderstichele H., Davidsson P., and Blennow K. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment. Acta Neurol. Scand. Suppl. 179 (2003) 47-51
71. Andreasen N., Minthon L., Vanmechelen E., Vanderstichele H., Davidsson P., Winblad B., and Blennow K. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci. Lett. 273 (1999) 5-8
72. Riemenschneider M., Lautenschlager N., Wagenpfeil S., Diehl J., Drzezga A., and Kurz A. Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. Arch. Neurol. 59 (2002) 1729-1734
73. DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment. Lancet Neurol. 2 (2003) 15-21
74. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., and Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23 (2007) 316-320
75. Wiltfang J., Esselmann H., Bibl M., Hull M., Hampel H., Kessler H., Frolich L., Schroder J., Peters O., Jessen F., Luckhaus C., Perneczky R., Jahn H., Fiszer M., Maler J.M., Zimmermann R., Bruckmoser R., Kornhuber J., and Lewczuk P. Amyloid beta peptide ratio 42/40 but not A beta 42 correlates with phospho-Tau in patients with low- and high-CSF A beta 40 load. J. Neurochem. 101 (2007) 1053-1059
76. Li G., Sokal I., Quinn J.F., Leverenz J.B., Brodey M., Schellenberg G.D., Kaye J.A., Raskind M.A., Zhang J., Peskind E.R., and Montine T.J. CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69 (2007) 631-639
77. Stomrud E., Hansson O., Blennow K., Minthon L., and Londos E. Cerebrospinal fluid biomarkers predict decline in subjective cognitive function over 3 years in healthy elderly. Dement. Geriatr. Cogn. Disord. 24 (2007) 118-124
78. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., Smith G.E., Younkin L.H., Petersen R.C., and Younkin S.G. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64 (2007) 354-362
79. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., and Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5 (2006) 655-660
80. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., and Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13 (2007) 1359-1362
81. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 (2001) 373-379
82. Mollenhauer B., Cepek L., Bibl M., Wiltfang J., Schulz-Schaeffer W.J., Ciesielczyk B., Neumann M., Steinacker P., Kretzschmar H.A., Poser S., Trenkwalder C., and Otto M. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement. Geriatr. Cogn. Disord. 19 (2005) 164-170
83. Kapaki E., Paraskevas G.P., Papageorgiou S.G., Bonakis A., Kalfakis N., Zalonis I., and Vassilopoulos D. Diagnostic value of CSF biomarker profile in frontotemporal lobar degeneration. Alzheimer Dis. Assoc. Disord. 22 (2008) 47-53
84. Sjogren M., Davidsson P., Wallin A., Granerus A.K., Grundstrom E., Askmark H., Vanmechelen E., and Blennow K. Decreased CSF-beta-amyloid 42 in Alzheimer's disease and amyotrophic lateral sclerosis may reflect mismetabolism of beta-amyloid induced by disparate mechanisms. Dement. Geriatr. Cogn. Disord. 13 (2002) 112-118
85. Hesse C., Rosengren L., Vanmechelen E., Vanderstichele H., Jensen C., Davidsson P., and Blennow K. Cerebrospinal fluid markers for Alzheimer's disease evaluated after acute ischemic stroke. J. Alzheimer's Dis. 2 (2000) 199-206
86. Kapaki E.N., Paraskevas G.P., Tzerakis N.G., Sfagos C., Seretis A., Kararizou E., and Vassilopoulos D. Cerebrospinal fluid tau, phospho-tau181 and beta-amyloid1-42 in idiopathic normal pressure hydrocephalus: a discrimination from Alzheimer's disease. Eur. J. Neurol. 14 (2007) 168-173
87. Vanderstichele H., De Vreese K., Blennow K., Andreasen N., Sindic C., Ivanoiu A., Hampel H., Burger K., Parnetti L., Lanari A., Padovani A., DiLuca M., Blaser M., Olsson A.O., Pottel H., Hulstaert F., and Vanmechelen E. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin. Chem. Lab. Med. 44 (2006) 1472-1480
88. Hampel H., Buerger K., Zinkowski R., Teipel S.J., Goernitz A., Andreasen N., Sjoegren M., DeBernardis J., Kerkman D., Ishiguro K., Ohno H., Vanmechelen E., Vanderstichele H., McCulloch C., Moller H.J., Davies P., and Blennow K. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry 61 (2004) 95-102
89. Buerger K., Zinkowski R., Teipel S.J., Arai H., DeBernardis J., Kerkman D., McCulloch C., Padberg F., Faltraco F., Goernitz A., Tapiola T., Rapoport S.I., Pirttila T., Moller H.J., and Hampel H. Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. Am. J. Psychiatry 160 (2003) 376-379
90. Buerger K., Zinkowski R., Teipel S.J., Tapiola T., Arai H., Blennow K., Andreasen N., Hofmann-Kiefer K., DeBernardis J., Kerkman D., McCulloch C., Kohnken R., Padberg F., Pirttila T., Schapiro M.B., Rapoport S.I., Moller H.J., Davies P., and Hampel H. Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. Arch. Neurol. 59 (2002) 1267-1272
91. Blasko I., Lederer W., Oberbauer H., Walch T., Kemmler G., Hinterhuber H., Marksteiner J., and Humpel C. Measurement of thirteen biological markers in CSF of patients with Alzheimer's disease and other dementias. Dement. Geriatr. Cogn. Disord. 21 (2006) 9-15
92. de Jong D., Jansen R.W., Kremer B.P., and Verbeek M.M. Cerebrospinal fluid amyloid beta42/phosphorylated tau ratio discriminates between Alzheimer's disease and vascular dementia. J. Gerontol. A. Biol. Sci. Med. Sci. 61 (2006) 755-758
93. Le Bastard N., Van Buggenhout M., De Leenheir E., Martin J.J., De Deyn P.P., and Engelborghs S. LOW specificity limits the use of the cerebrospinal fluid AB1-42/P-TAU181P ratio to discriminate Alzheimer's disease from vascular dementia. J. Gerontol. A. Biol. Sci. Med. Sci. 62 (2007) 923-924 author reply 924-925
94. Petzold A. Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss. J. Neurol. Sci. 233 (2005) 183-198
95. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., and Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J. Neurochem. 67 (1996) 2013-2018
96. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., and Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 52 (1999) 1090-1093
97. Mocali A., Cedrola S., Della Malva N., Bontempelli M., Mitidieri V.A., Bavazzano A., Comolli R., Paoletti F., and La Porta C.A. Increased plasma levels of soluble CD40, together with the decrease of TGF beta 1, as possible differential markers of Alzheimer disease. Exp. Gerontol. 39 (2004) 1555-1561
98. Yasutake C., Kuroda K., Yanagawa T., Okamura T., and Yoneda H. Serum BDNF, TNF-alpha and IL-1beta levels in dementia patients: comparison between Alzheimer's disease and vascular dementia. Eur. Arch. Psychiatry Clin. Neurosci. 256 (2006) 402-406
99. Emanuele E., D'Angelo A., Tomaino C., Binetti G., Ghidoni R., Politi P., Bernardi L., Maletta R., Bruni A.C., and Geroldi D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62 (2005) 1734-1736
100. Butterfield D.A., Reed T., Newman S.F., and Sultana R. Roles of amyloid beta-peptide-associated oxidative stress and brain protein modifications in the pathogenesis of Alzheimer's disease and mild cognitive impairment. Free Radic. Biol. Med. 43 (2007) 658-677
101. Dovey H.F., John V., Anderson J.P., Chen L.Z., de Saint Andrieu P., Fang L.Y., Freedman S.B., Folmer B., Goldbach E., Holsztynska E.J., Hu K.L., Johnson-Wood K.L., Kennedy S.L., Kholodenko D., Knops J.E., Latimer L.H., Lee M., Liao Z., Lieberburg I.M., Motter R.N., Mutter L.C., Nietz J., Quinn K.P., Sacchi K.L., Seubert P.A., Shopp G.M., Thorsett E.D., Tung J.S., Wu J., Yang S., Yin C.T., Schenk D.B., May P.C., Altstiel L.D., Bender M.H., Boggs L.N., Britton T.C., Clemens J.C., Czilli D.L., Dieckman-McGinty D.K., Droste J.J., Fuson K.S., Gitter B.D., Hyslop P.A., Johnstone E.M., Li W.Y., Little S.P., Mabry T.E., Miller F.D., and Audia J.E. Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain. J. Neurochem. 76 (2001) 173-181
102. De Strooper B., Annaert W., Cupers P., Saftig P., Craessaerts K., Mumm J.S., Schroeter E.H., Schrijvers V., Wolfe M.S., Ray W.J., Goate A., and Kopan R. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain. Nature 398 (1999) 518-522
103. Siemers E., Skinner M., Dean R.A., Gonzales C., Satterwhite J., Farlow M., Ness D., and May P.C. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin. Neuropharmacol. 28 (2005) 126-132
104. Siemers E.R., Quinn J.F., Kaye J., Farlow M.R., Porsteinsson A., Tariot P., Zoulnouni P., Galvin J.E., Holtzman D.M., Knopman D.S., Satterwhite J., Gonzales C., Dean R.A., and May P.C. Effects of a gamma-secretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 66 (2006) 602-604
105. Siemers E.R., Dean R.A., Friedrich S., Ferguson-Sells L., Gonzales C., Farlow M.R., and May P.C. Safety, tolerability, and effects on plasma and cerebrospinal fluid amyloid-beta after inhibition of gamma-secretase. Clin. Neuropharmacol. 30 (2007) 317-325
106. Anderson J.J., Holtz G., Baskin P.P., Turner M., Rowe B., Wang B., Kounnas M.Z., Lamb B.T., Barten D., Felsenstein K., McDonald I., Srinivasan K., Munoz B., and Wagner S.L. Reductions in beta-amyloid concentrations in vivo by the gamma-secretase inhibitors BMS-289948 and BMS-299897. Biochem. Pharmacol. 69 (2005) 689-698
107. Barten D.M., Guss V.L., Corsa J.A., Loo A., Hansel S.B., Zheng M., Munoz B., Srinivasan K., Wang B., Robertson B.J., Polson C.T., Wang J., Roberts S.B., Hendrick J.P., Anderson J.J., Loy J.K., Denton R., Verdoorn T.A., Smith D.W., and Felsenstein K.M. Dynamics of {beta}-amyloid reductions in brain, cerebrospinal fluid, and plasma of {beta}-amyloid precursor protein transgenic mice treated with a {gamma}-secretase inhibitor. J. Pharmacol. Exp. Ther. 312 (2005) 635-643
108. Best J.D., Jay M.T., Otu F., Churcher I., Reilly M., Morentin-Gutierrez P., Pattison C., Harrison T., Shearman M.S., and Atack J.R. In vivo characterization of Abeta(40) changes in brain and cerebrospinal fluid using the novel gamma-secretase inhibitor N-[cis-4-[(4-chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1, 1-trifluoromethanesulfonamide (MRK-560) in the rat. J. Pharmacol. Exp. Ther. 317 (2006) 786-790
109. Best J.D., Jay M.T., Otu F., Ma J., Nadin A., Ellis S., Lewis H.D., Pattison C., Reilly M., Harrison T., Shearman M.S., Williamson T.L., and Atack J.R. Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-l-alaninamide]. J. Pharmacol. Exp. Ther. 313 (2005) 902-908
110. Shibata M., Yamada S., Kumar S.R., Calero M., Bading J., Frangione B., Holtzman D.M., Miller C.A., Strickland D.K., Ghiso J., and Zlokovic B.V. Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier. J. Clin. Invest. 106 (2000) 1489-1499
111. Cirrito J.R., Deane R., Fagan A.M., Spinner M.L., Parsadanian M., Finn M.B., Jiang H., Prior J.L., Sagare A., Bales K.R., Paul S.M., Zlokovic B.V., Piwnica-Worms D., and Holtzman D.M. P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J. Clin. Invest. 115 (2005) 3285-3290
112. Deane R., Du Yan S., Submamaryan R.K., LaRue B., Jovanovic S., Hogg E., Welch D., Manness L., Lin C., Yu J., Zhu H., Ghiso J., Frangione B., Stern A., Schmidt A.M., Armstrong D.L., Arnold B., Liliensiek B., Nawroth P., Hofman F., Kindy M., Stern D., and Zlokovic B. RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat. Med. 9 (2003) 907-913
113. Freeman S.H., Raju S., Hyman B.T., Frosch M.P., and Irizarry M.C. Plasma Abeta levels do not reflect brain Abeta levels. J. Neuropathol. Exp. Neurol. 66 (2007) 264-271
114. Grimwood S., Hogg J., Jay M.T., Lad A.M., Lee V., Murray F., Peachey J., Townend T., Vithlani M., Beher D., Shearman M.S., and Hutson P.H. Determination of guinea-pig cortical gamma-secretase activity ex vivo following the systemic administration of a gamma-secretase inhibitor. Neuropharmacology 48 (2005) 1002-1011
115. Weksler M.E., Relkin N., Turkenich R., LaRusse S., Zhou L., and Szabo P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol. 37 (2002) 943-948
116. Dodel R., Hampel H., Depboylu C., Lin S., Gao F., Schock S., Jackel S., Wei X., Buerger K., Hoft C., Hemmer B., Moller H.J., Farlow M., Oertel W.H., Sommer N., and Du Y. Human antibodies against amyloid beta peptide: a potential treatment for Alzheimer's disease. Ann. Neurol. 52 (2002) 253-256
117. Janus C., Pearson J., McLaurin J., Mathews P.M., Jiang Y., Schmidt S.D., Chishti M.A., Horne P., Heslin D., French J., Mount H.T., Nixon R.A., Mercken M., Bergeron C., Fraser P.E., St George-Hyslop P., and Westaway D. A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature 408 (2000) 979-982
118. Morgan D., Diamond D.M., Gottschall P.E., Ugen K.E., Dickey C., Hardy J., Duff K., Jantzen P., DiCarlo G., Wilcock D., Connor K., Hatcher J., Hope C., Gordon M., and Arendash G.W. A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408 (2000) 982-985
119. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., and Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400 (1999) 173-177
120. Gilman S., Koller M., Black R.S., Jenkins L., Griffith S.G., Fox N.C., Eisner L., Kirby L., Rovira M.B., Forette F., and Orgogozo J.M. Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 64 (2005) 1553-1562
121. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., and Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 61 (2003) 46-54
122. Jianping L., Zhibing Y., Wei Q., Zhikai C., Jie X., and Jinbiao L. Low avidity and level of serum anti-Abeta antibodies in Alzheimer disease. Alzheimer Dis. Assoc. Disord. 20 (2006) 127-132
123. Mruthinti S., Buccafusco J.J., Hill W.D., Waller J.L., Jackson T.W., Zamrini E.Y., and Schade R.F. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol. Aging 25 (2004) 1023-1032
124. Gustaw K.A., Garrett M.R., Lee H.G., Castellani R.J., Zagorski M.G., Prakasam A., Siedlak S.L., Zhu X., Perry G., Petersen R.B., Friedland R.P., and Smith M.A. Antigen-antibody dissociation in Alzheimer disease: a novel approach to diagnosis. J. Neurochem. 106 (2008) 1350-1356
125. Relkin N.R., Szabo P., Adamiak B., Burgut T., Monthe C., Lent R.W., Younkin S., Younkin L., Schiff R., and Weksler M.E. 18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol. Aging (2008) 10.1016/j.neurobiolaging.2007.12.021
126. Pfeifer M., Boncristiano S., Bondolfi L., Stalder A., Deller T., Staufenbiel M., Mathews P.M., and Jucker M. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 298 (2002) 1379
127. Poduslo J.F., Ramakrishnan M., Holasek S.S., Ramirez-Alvarado M., Kandimalla K.K., Gilles E.J., Curran G.L., and Wengenack T.M. In vivo targeting of antibody fragments to the nervous system for Alzheimer's disease immunotherapy and molecular imaging of amyloid plaques. J. Neurochem. 102 (2007) 420-433
128. Thongboonkerd V. Practical points in urinary proteomics. J. Proteome. Res. 6 (2007) 3881-3890
129. Montine T.J., Quinn J., Kaye J., and Morrow J.D. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J. Mol. Neurosci. 33 (2007) 114-119
130. Levy S., McConville M., Lazaro G.A., and Averback P. Competitive ELISA studies of neural thread protein in urine in Alzheimer's disease. J. Clin. Lab. Anal. 21 (2007) 24-33
131. Ghanbari H., Ghanbari K., Beheshti I., Munzar M., Vasauskas A., and Averback P. Biochemical assay for AD7C-NTP in urine as an Alzheimer's disease marker. J. Clin. Lab. Anal. 12 (1998) 285-288
132. Monte S.M., Ghanbari K., Frey W.H., Beheshti I., Averback P., Hauser S.L., Ghanbari H.A., and Wands J.R. Characterization of the AD7C-NTP cDNA expression in Alzheimer's disease and measurement of a 41-kD protein in cerebrospinal fluid. J. Clin. Invest. 100 (1997) 3093-3104
133. de la Monte S.M., and Wands J.R. The AD7c-ntp neuronal thread protein biomarker for detecting Alzheimer's disease. Front Biosci. 7 (2002) d989-996
134. Fassbender K., Simons M., Bergmann C., Stroick M., Lutjohann D., Keller P., Runz H., Kuhl S., Bertsch T., von Bergmann K., Hennerici M., Beyreuther K., and Hartmann T. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 5856-5861
135. Riekse R.G., Li G., Petrie E.C., Leverenz J.B., Vavrek D., Vuletic S., Albers J.J., Montine T.J., Lee V.M., Lee M., Seubert P., Galasko D., Schellenberg G.D., Hazzard W.R., and Peskind E.R. Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J. Alzheimer's Dis. 10 (2006) 399-406
136. Hoglund K., Thelen K.M., Syversen S., Sjogren M., von Bergmann K., Wallin A., Vanmechelen E., Vanderstichele H., Lutjohann D., and Blennow K. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 19 (2005) 256-265
137. Carlsson C.M., Gleason C.E., Hess T.M., Moreland K.A., Blazel H.M., Koscik R.L., Schreiber N.T., Johnson S.C., Atwood C.S., Puglielli L., Hermann B.P., McBride P.E., Stein J.H., Sager M.A., and Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J. Alzheimer's Dis. 13 (2008) 187-197
138. Degerman Gunnarsson M., Kilander L., Basun H., and Lannfelt L. Reduction of phosphorylated tau during memantine treatment of Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 24 (2007) 247-252
139. Parnetti L., Amici S., Lanari A., Romani C., Antognelli C., Andreasen N., Minthon L., Davidsson P., Pottel H., Blennow K., and Gallai V. Cerebrospinal fluid levels of biomarkers and activity of acetylcholinesterase (AChE) and butyrylcholinesterase in AD patients before and after treatment with different AChE inhibitors. Neurol. Sci. 23 Suppl. 2 (2002) S95-S96
140. Friedland R.P., Fritsch T., Smyth K.A., Koss E., Lerner A.J., Chen C.H., Petot G.J., and Debanne S.M. Patients with Alzheimer's disease have reduced activities in midlife compared with healthy control-group members. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 3440-3445
141. Laurin D., Verreault R., Lindsay J., MacPherson K., and Rockwood K. Physical activity and risk of cognitive impairment and dementia in elderly persons. Arch. Neurol. 58 (2001) 498-504
142. Wilson R.S., Mendes De Leon C.F., Barnes L.L., Schneider J.A., Bienias J.L., Evans D.A., and Bennett D.A. Participation in cognitively stimulating activities and risk of incident Alzheimer disease. JAMA 287 (2002) 742-748
143. Adlard P.A., Perreau V.M., Pop V., and Cotman C.W. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J. Neurosci. 25 (2005) 4217-4221
144. Nichol K.E., Parachikova A.I., and Cotman C.W. Three weeks of running wheel exposure improves cognitive performance in the aged Tg2576 mouse. Behav. Brain Res. 184 (2007) 124-132
145. Nichol K.E., Poon W.W., Parachikova A.I., Cribbs D.H., Glabe C.G., and Cotman C.W. Exercise alters the immune profile in Tg2576 Alzheimer mice toward a response coincident with improved cognitive performance and decreased amyloid. J. Neuroinflammation. 5 (2008) 13
146. Parachikova A., Nichol K.E., and Cotman C.W. Short-term exercise in aged Tg2576 mice alters neuroinflammation and improves cognition. Neurobiol. Dis. 30 (2008) 121-129
147. Jankowsky J.L., Melnikova T., Fadale D.J., Xu G.M., Slunt H.H., Gonzales V., Younkin L.H., Younkin S.G., Borchelt D.R., and Savonenko A.V. Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J. Neurosci. 25 (2005) 5217-5224
148. Berardi N., Braschi C., Capsoni S., Cattaneo A., and Maffei L. Environmental enrichment delays the onset of memory deficits and reduces neuropathological hallmarks in a mouse model of Alzheimer-like neurodegeneration. J. Alzheimers. Dis. 11 (2007) 359-370
149. www.nymox.com/products/alzheimalert/clinical_summary.html
150. Kim M.R., and Kim C.W. Human blood plasma preparation for two-dimensional gel electrophoresis. J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 849 (2007) 203-210
151. Strozyk D., Blennow K., White L.R., and Launer L.J. CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study. Neurology 60 (2003) 652-656
152. Finehout E.J., Franck Z., Choe L.H., Relkin N., and Lee K.H. Cerebrospinal fluid proteomic biomarkers for Alzheimer's disease. Ann. Neurol. 61 (2007) 120-129
153. Ewers M., Buerger K., Teipel S.J., Scheltens P., Schroder J., Zinkowski R.P., Bouwman F.H., Schonknecht P., Schoonenboom N.S., Andreasen N., Wallin A., DeBernardis J.F., Kerkman D.J., Heindl B., Blennow K., and Hampel H. Multicenter assessment of CSF-phosphorylated tau for the prediction of conversion of MCI. Neurology 69 (2007) 2205-2212
154. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., and Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging (2008) 10.1016/j.neurobiolaging.2008.03.027
155. de Jong D., Jansen R.W., Pijnenburg Y.A., van Geel W.J., Borm G.F., Kremer H.P., and Verbeek M.M. CSF neurofilament proteins in the differential diagnosis of dementia. J. Neurol. Neurosurg. Psychiatry 78 (2007) 936-938
156. De Servi B., La Porta C.A., Bontempelli M., and Comolli R. Decrease of TGF-beta1 plasma levels and increase of nitric oxide synthase activity in leukocytes as potential biomarkers of Alzheimer's disease. Exp. Gerontol. 37 (2002) 813-821
157. Rodriguez-Rodriguez E., Sanchez-Juan P., Mateo I., Llorca J., Infante J., Garcia-Gorostiaga I., Berciano J., and Combarros O. Serum levels and genetic variation of TGF-beta1 are not associated with Alzheimer's disease. Acta Neurol. Scand. 116 (2007) 409-412
158. El Mouedden M., Vandermeeren M., Meert T., and Mercken M. Reduction of Abeta levels in the Sprague Dawley rat after oral administration of the functional gamma-secretase inhibitor, DAPT: a novel non-transgenic model for Abeta production inhibitors. Curr. Pharm. Des. 12 (2006) 671-676
159. Dodel R.C., Du Y., Depboylu C., Hampel H., Frolich L., Haag A., Hemmeter U., Paulsen S., Teipel S.J., Brettschneider S., Spottke A., Nolker C., Moller H.J., Wei X., Farlow M., Sommer N., and Oertel W.H. Intravenous immunoglobulins containing antibodies against beta-amyloid for the treatment of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1472-1474